menu search

89bio publishes positive results from phase 2 entrigue trial of pegozafermin in patients with severe hypertriglyceridemia (shtg) in nature medicine

– Published data showed consistent and significant reductions in triglycerides, atherogenic lipoproteins and liver fat, and pegozafermin’s favorab...

June 24, 2023, 9:05 am

Amarin partner eddingpharm receives regulatory approval for vascepa® (icosapent ethyl) in mainland china

— VASCEPA Approved by the National Medical Products Administration (NMPA) as an Adjunct to Diet to Reduce Triglyceride Levels in Adult Patients with...

June 1, 2023, 10:00 am

Why shares of 89bio soared this week

89bio's lead therapy pegozafermin is seen as a treatment for NASH and hypertriglyceridemia. No NASH dru...

March 24, 2023, 10:57 am

89bio presents new analysis of data from phase 2 entrigue trial of pegozafermin in patients with severe hypertriglyceridemia (shtg) at american college of cardiology’s annual scientific session togeth

– Post hoc analysis data demonstrated pegozafermin treatment significantly reduced triglycerides and other atherogenic lipids in patients with SHTG ...

March 4, 2023, 6:30 pm

89bio presents new analysis of data from phase 2 entrigue trial of pegozafermin in patients with severe hypertriglyceridemia (shtg) at american college of cardiology’s annual scientific session togeth

– Post hoc analysis data demonstrated pegozafermin treatment significantly reduced triglycerides and other atherogenic lipids in patients with SHTG ...

March 4, 2023, 6:30 pm

89bio presents new analysis of data from phase 2 entrigue trial of pegozafermin in patients with severe hypertriglyceridemia (shtg) at american college of cardiology’s annual scientific session togeth

– Post hoc analysis data demonstrated pegozafermin treatment significantly reduced triglycerides and other atherogenic lipids in patients with SHTG ...

March 4, 2023, 6:30 pm

89bio presents new analysis of data from phase 2 entrigue trial of pegozafermin in patients with severe hypertriglyceridemia (shtg) at american college of cardiology’s annual scientific session togeth

– Post hoc analysis data demonstrated pegozafermin treatment significantly reduced triglycerides and other atherogenic lipids in patients with SHTG ...

March 4, 2023, 6:30 pm

89bio presents new analysis of data from phase 2 entrigue trial of pegozafermin in patients with severe hypertriglyceridemia (shtg) at american college of cardiology’s annual scientific session togeth

– Post hoc analysis data demonstrated pegozafermin treatment significantly reduced triglycerides and other atherogenic lipids in patients with SHTG ...

March 4, 2023, 6:30 pm

89bio to present additional pegozafermin data in severe hypertriglyceridemia from phase 2 entrigue study at american college of cardiology's annual scientific session together with world congress of c

SAN FRANCISCO, Feb. 21, 2023 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and...

February 21, 2023, 8:00 am

89bio to present additional pegozafermin data in severe hypertriglyceridemia from phase 2 entrigue study at american college of cardiology's annual scientific session together with world congress of c

SAN FRANCISCO, Feb. 21, 2023 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and...

February 21, 2023, 8:00 am

89bio to present additional pegozafermin data in severe hypertriglyceridemia from phase 2 entrigue study at american college of cardiology's annual scientific session together with world congress of c

SAN FRANCISCO, Feb. 21, 2023 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and...

February 21, 2023, 8:00 am

Medicinova receives a notice of allowance for a new patent covering mn-001 and mn-002 for the treatment of hypertriglyceridemia, hypercholesterolemia, and hyperlipoproteinemia in brazil

LA JOLLA, Calif., Jan. 09, 2023 (GLOBE NEWSWIRE) — MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) an...

January 10, 2023, 3:00 am

This analyst thinks 89bio's pegozafermin data has exceeded expectations

In June, 89bio Inc (NASDAQ: ETNB) announced topline results from the ENTRIGUE Phase 2 proof-of-concept study of pegozafermin for severe ...

July 11, 2022, 2:24 pm

89bio posts promising pegozafermin data for severe hypertriglyceridemia

89bio Inc (NASDAQ: ETNB) announced topline results from the ENTRIGUE Phase 2 proof-of-concept study of pegozafermin for severe ...

June 29, 2022, 6:07 am

Ionis, pfizer scrap plans for experimental cardiovascular drug

Shares of Ionis Pharmaceuticals Inc. IONS, +5.11% fell 7.9% in premarket trading on Monday after the company and Pfizer Inc. PFE, +1.80% said they dis...

January 31, 2022, 7:41 am

Ionis, pfizer scrap plans for experimental cardiovascular drug

Shares of Ionis Pharmaceuticals Inc. IONS, +5.11% fell 7.9% in premarket trading on Monday after the company and Pfizer Inc. PFE, +1.80% said they dis...

January 31, 2022, 7:41 am

Ionis, pfizer scrap plans for experimental cardiovascular drug

Shares of Ionis Pharmaceuticals Inc. IONS, +5.11% fell 7.9% in premarket trading on Monday after the company and Pfizer Inc. PFE, +1.80% said they dis...

January 31, 2022, 7:41 am

Liminal biosciences pauses development of fezagepras, outlines r&d priorities for 2022

Following the analysis of the preliminary pharmacokinetic data from the Phase I MAD trial, Liminal BioSciences Inc (NASDAQ: LMNL) said that it woul...

January 20, 2022, 6:52 am

Liminal biosciences pauses development of fezagepras, outlines r&d priorities for 2022

Following the analysis of the preliminary pharmacokinetic data from the Phase I MAD trial, Liminal BioSciences Inc (NASDAQ: LMNL) said that it woul...

January 20, 2022, 6:52 am

Liminal biosciences pauses development of fezagepras, outlines r&d priorities for 2022

Following the analysis of the preliminary pharmacokinetic data from the Phase I MAD trial, Liminal BioSciences Inc (NASDAQ: LMNL) said that it woul...

January 20, 2022, 6:52 am


Search within

Pages Search Results: